Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

   

Sepranolone receives FDA IND approval in menstrual migraine

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile. 

Full PDF
   

Asarina Pharma issues new shares to Ergomed plc

(Stockholm, June 4, 2019) Asarina Pharma AB (publ) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 8 May 2019, issue 246,434 new shares to Ergomed plc (“Ergomed”), the CRO carrying out its Phase IIb PMDD study.

Full PDF
   

Asarina Pharma AB (publ) Interim Report, Q1 2019 released

(Stockholm May 20, 2019) Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management – leading to a solid cash position at the end of the First Quarter.”

Full PDF
Asarina-Pharma Q1-2019 master2
   

Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019

(Stockholm May 8, 2019) On 8 May 2019, the Annual General Meeting (”AGM”) of Asarina Pharma AB (publ) was held in Stockholm. Read below for a summary of the decisions made.

Full PDF
   

Asarina Pharma Annual Report for 2018 released

(Stockholm April 17 2019) Asarina Pharma AB today announces that its Annual Report for 2018 is now available on the company’s website.

Full PDF
Asarina-Pharma annual-report2018-ENG